FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

Not Applicable

Not yet recruiting

• Conditions: Relapse Multiple Myeloma; Refractory Multiple Myeloma
• Interventions: Biological: FT836 CAR T cells (1 x 10^8 cells per dose); Biological: FT836 CAR T cells (3 x 108 cells per dose); Biological: FT836 CAR T cells (up to 9 x 108 cells per dose); Drug: Daratumumab 16 mg/kg

• Registration Number: NCT07221032
• Lead Sponsor: Medical College of Wisconsin

Brief Summary

This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-10
• Study First Submitted: 2025-10-23
• Study First Submitted QC: 2025-10-23
• Last Update Submitted: 2025-10-23
• Study First Posted: 2025-10-27
• Last Update Posted: 2025-10-27
• Study Start: 2026-03-01
• Primary Completion: 2028-03
• Study Completion: 2030-03-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Patients must ≥18 years and < 80 years old.

2. Patients must have received >=3 prior lines of therapies, including proteasome inhibitor, immunomodulator and a CD38 monoclonal antibody:

   • International Myeloma Working Group (IMWG) criteria define refractory disease as disease progression on or within 60 days of receiving therapy.

3. Patients must have measurable disease, including at least one or more of the following criteria:

   1. Serum M-protein ≥ 0.5 g/dl;
   2. Urine M-protein ≥ 200 mg/24 hrs;
   3. Involved serum light chain ≥100 mg/L with abnormal light chain ratio;

4. Karnofsky performance score ≥70.

5. Adequate hepatic function, defined as:

   1. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase <3x upper limit of normal (ULN);
   2. Serum bilirubin <2.0 mg/dL except for patients with Gilbert's syndrome, who must have serum bilirubin of <3 mg/dL.

6. Absolute neutrophil count (ANC) ≥1,000 with no G-CSF within 72 hours or pegylated G-CSF within 10 days.

7. Platelets ≥50,000 with no transfusion within 72 hours of eligibility testing.

8. Adequate renal function, defined as creatinine clearance ≥50 mL/min calculated using the Cockroft-Gault formula.

9. Able to provide written informed consent.

10. Agree to practice birth control during the study.

11. Adequate cardiac function as indicated by New York Heart Association (NYHA) classification I or II AND left ventricular ejection fraction of ≥45% -- by cardiac echocardiogram (ECHO) or multigated acquisition scan (MUGA) -- and adequate pulmonary function as indicated by room air oxygen saturation of ≥90%.

12. Expected survival >12 weeks.

13. Negative urine or serum pregnancy test in females of childbearing potential at study entry.

14. No contraindication to central line access. Female subjects of reproductive potential (women who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure [hysterectomy or bilateral oophorectomy]) must have a negative serum or urine pregnancy test performed as part of the eligibility criteria. Lactating women are eligible for this study but will be asked not to provide breast milk to their child from Day -11 through Day +90 after CAR T-cell therapy. It is possible they may no longer be able to lactate after receiving chemotherapy and treatment.

Due to the high-risk level of this study, while enrolled, all subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). Additionally, if participating in sexual activity that could lead to pregnancy, the study subject must agree to use reliable and double-barrier methods of contraception during the follow-up period of the protocol.

Acceptable birth control includes a combination of two of the following methods:

• Condoms (male or female) with or without a spermicidal agent.
• Diaphragm or cervical cap with spermicide.
• Intrauterine device (IUD).
• Hormonal-based contraception. Subjects who are not of reproductive potential (women who are premenarche or have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy, tubal ligation, salpingectomy, and/or bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraception.

Exclusion Criteria

1. Positive beta-Human Chorionic Gonadotropin (HCG) in female of child-bearing potential.

2. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.

3. History of significant autoimmune disease OR active, uncontrolled autoimmune phenomenon requiring steroid therapy defined as >20 mg of prednisone or equivalent daily.

4. Presence of ≥ Grade 3 non-hematologic toxicities as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 from any previous treatment unless it is felt to be due to underlying disease.

5. Concurrent use of investigational therapeutic agents or enrollment in another therapeutic clinical trial at any institution. A minimum of 14 days or five half-lives of the drug (whichever is shorter) washout prior to start of daratumumab.

6. Refusal to participate in the long-term follow-up protocol.

7. Patients with active Central Nervous System (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or by lumbar puncture.

   a. Patients with prior CNS disease that has been effectively treated will be eligible providing last treatment was ≥2 weeks before start of daratumumab and a remission documented within four weeks of planned CAR T-cell infusion by MRI brain and Cerebrospinal Fluid (CSF) analysis.

8. Previous recipients of allogeneic hematopoietic stem cell transplantation (AHCT) are excluded if they are <6 months post-transplant, have evidence of active graft-versus-host-disease (GVHD) of any grade, or are currently on immunosuppression.

9. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, and AL amyloidosis.

10. Prior treatment with gene therapy or any gene-modified cellular therapy.

11. Cytotoxic chemotherapy, oral chemotherapeutic agents, or antibody-directed treatment within 14 days of starting daratumumab or after starting daratumumab.

    1. Corticosteroids are allowable up until seven days prior to starting daratumumab and after starting daratumumab for disease control up until the day prior to cell infusion (Day -1).
    2. Radiation is allowed to a single symptomatic site.

12. Patients post solid organ transplant who develop high-grade lymphomas or leukemias.

13. Concurrent active malignancy other than basal or squamous cell carcinomas of the skin.

14. Active bacterial, viral, or fungal infection requiring systemic treatment.

15. Patients who have received major surgery one week prior to starting daratumumab and three weeks prior to lymphodepletion.

16. Active malignancy that required therapy in the last two years except successfully treated non-metastatic basal or squamous cell carcinoma, or prostate carcinoma that does not require therapy. Other similar conditions may be discussed with and permitted by the medical monitor.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
FT836 CAR T cells (1 x 10^8 cells per dose)	FT836 CAR T cells (1 x 10^8 cells per dose)	This is Dose Level 0 (de-escalation dose).
FT836 CAR T cells (1 x 10^8 cells per dose)	Daratumumab 16 mg/kg	This is Dose Level 0 (de-escalation dose).
FT836 CAR T cells (3 x 108 cells per dose)	FT836 CAR T cells (3 x 108 cells per dose)	This is Dose Level 1 (starting dose).
FT836 CAR T cells (3 x 108 cells per dose)	Daratumumab 16 mg/kg	This is Dose Level 1 (starting dose).
FT836 CAR T cells (up to 9 x 108 cells per dose)	FT836 CAR T cells (up to 9 x 108 cells per dose)	This is Dose Level 2, which is ≤3 times Dose Level 1.
FT836 CAR T cells (up to 9 x 108 cells per dose)	Daratumumab 16 mg/kg	This is Dose Level 2, which is ≤3 times Dose Level 1.

Primary Outcome Measures

Name	Time	Method
Incidence of Grade 3 or higher adverse events	start of therapy through 30 days after the end of study therapy, up to 2 years	This measure is the number of Grade 3 or higher adverse events possibly, probably, or definitely related to the study therapy. Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded and assessed using the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading systems. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) will be graded and assessed using the ASTCT panel guidelines.

Trial Locations

Locations (1)

Froedtert & the Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States